Yasmine Hassan, Director of Global Oncology Policy, Advocacy, and Health Equity at AstraZeneca, shared a post on LinkedIn:
“I’m pleased to share that AstraZeneca’s global Bladder Cancer Council shared its first research at ISPOR—The Professional Society for Health Economics and Outcomes Research 2026, a conference dedicated to advancing patient-centred care through health economics and outcomes research.
We established the Council in 2024, with a clear ambition to bring together clinicians and patient advocates to help transform care and improve outcomes for people affected by bladder cancer.
The study explored patient attitudes towards shared decision-making and innovation in muscle-invasive bladder cancer (MIBC). The findings reinforce how important it is to understand what matters most to patients and ensure healthcare systems are equipped to support informed, shared decisions about their treatment and care.
Thank you to every Council member for driving this work, and to the patients and patient advocates from seven countries across Europe and North America who contributed their time, experience and insights.
Partnerships like these are essential because meaningful change can only happen through co-creation: listening, learning and working together.
After the inspiring conversations at ISPOR 2026, I’m looking forward to pushing forward work to ensure people living with bladder cancer have their voices heard in a meaningful way.”
Title: Patient Attitudes to Shared Decision-Making and Innovations in Muscle Invasive Bladder Cancer: A Multi-Country Focus Group
Authors: C. Daniel Mullins, Lazar Popovic, Hein van Poppel, Maarten Postma, Christopher Wallis, Alex Filicevas, Nimira Alimohamed, Igor Tomaškovic
Other articles featuring Yasmine Hassan on OncoDaily.